ArticleDiabetology & metabolic syndrome2026
Multi-omic profiling reveals Retatrutide alleviates adipose tissue fibrosis via metabolic reprogramming and tissue repair.
Article in Diabetology & metabolic syndrome, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundRetatrutide, a novel GIP, GLP-1, and glucagon receptor triple agonist, exhibits unprecedented weight-reducing efficacy in clinical trials, yet the molecular basis of its systemic metabolic benefits remains unclear.
methodsUsing a high-fat diet–induced obesity mouse model, we investigated the effects of Retatrutide on adipose tissue through integrated physiological, histological, transcriptomic, and metabolomic analyses.
resultsRetatrutide markedly reduced body weight and adiposity and improved metabolic parameters including glucose homeostasis and dyslipidemia. Multi-omic profiling revealed a coordinated reprogramming of epididymal white adipose tissue, characterized by suppressed lipogenesis, enhanced fatty acid oxidation and mitochondrial function, restored peroxisomal activity, and downregulated inflammatory/fibrotic pathways while promoting angiogenic/reparative signaling. Metabolomic analysis further demonstrated clearance of lipotoxic intermediates, decreased pro-inflammatory lipids, reduced collagen-derived metabolites, and elevated anti-inflammatory 15-HETE, confirming metabolic restoration at multiple regulatory levels.
conclusionsRetatrutide transforms dysfunctional white adipose tissue into a metabolically competent organ by simultaneously enhancing lipid oxidation, suppressing inflammation and fibrotic remodeling, and restoring endocrine function. These findings identify adipose tissue as an important therapeutic target of triple incretin agonism and establish tissue quality restoration—rather than mere mass reduction—as a new therapeutic paradigm for obesity and related metabolic disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.